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strategies T16/I3,I3 and I3/T12,T12 were dominated by
T16/I3,T12. The incremental analysis vs. strategy T12/
I3,T12 indicated, that T16/I3,T12 and I4/T12,T12 were
not cost-effective alternatives for T12/I3,T12 with ICER
14 743 and 19 687 PLN/mycological cure gained, respec-
tively. Changing the values of key drivers in the sensitiv-
ity analysis did not have any significant effect on ICER.
CONCLUSION: T12 as primary treatment with I3 as
treatment of failure and T12 as treatment of re-infection
was the most cost-effective treatment for toenail onycho-
mycosis in Poland.
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OBJECTIVE: Upper respiratory tract infections are fre-
quent in children. Their economic impact is widely un-
known. This study responded to a request from the
French Economic Committee to estimate the direct cost
of an acute rhino-pharyngitis (ARP), the effectiveness of
Imocur® (OM-85 BV indicated for the prevention of re-
currences), and the cost effectiveness of this strategy com-
pared to placebo from a Social Security perspective.
METHOD: Costs, probabilities of short-term complica-
tions, associated care, effectiveness of Imocur during the
winter period were based on review of the literature, na-
tional health statistics and consulting experts’ opinions.
An incremental cost-effectiveness model was used.
RESULTS: The mean direct cost for an ARP is €49.5.
Among children with recurrent infection, 1.52 infections
during the winter period is avoided using this type of pre-
vention and Social Security saves approximately €68 per
child on the cost of care. The sensitivity analyses confirm
the robustness of the model, and show that prevention
with Imocur allowed Social Security to save between 28
and 304 € in direct costs for each at-risk individual who
received preventive treatment. The threshold analysis
shows that this type of prophylaxis is economically prof-
itable for the community starting from 0,15 prevented in-
fections and direct costs of care of an acute infection
exceeding 4.77 €. The demonstration is valid with recur-
rently-infected children, a population for which the effec-
tiveness of Imocur has been established. If we had taken
into account other payers’ viewpoints and the indirect
costs, our conclusions would have been reinforced.
CONCLUSION: Non-specific immunotherapy is a rea-
sonable measure to be considered for prevention of recur-
rences and should be associated with recommended mea-
sures in children at risk. The French health authorities
considered the economic value of an effective medication
to the community in assessing its usefulness.
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OBJECTIVES: Morbidity due to respiratory infections
leads to significant adverse societal and economic conse-
quences. This study investigates the extent to which treat-
ment for respiratory infections imposes a financial burden
on an employer, and documents variations in employer
payments between specific respiratory infections.
METHODS: The data source is a rich administrative
claims database for a national, Fortune 100 manufac-
turer. It includes 1997 medical, pharmaceutical, and dis-
ability claims for employees, spouses, dependents, and re-
tirees (n  100,000) under age 65. The research sample
consists of individual patients with one or more medical
or disability claims for at least one of eleven infectious re-
spiratory conditions. Resource utilization is contrasted
with a 10 percent random sample of the employer’s over-
all beneficiary population.
RESULTS: Direct (medical and pharmaceutical) and in-
direct (disability and sporadic absenteeism) costs are an-
alyzed. The average per capita annual costs are: for the
entire employer population, $2,368; for all respiratory-
infection patients, $4,397, and for respiratory-infection
employees eligible for disability, $6,838. Total costs for
respiratory-infection patients are 1.8 times those for the
typical beneficiary. Total costs are highest for patients
with pneumonia ($11,544) and lowest for patients with
acute tonsillitis and acute pharyngitis ($2,180). Medical
and pharmaceutical treatments account for 65% of total
costs for all employees with respiratory infections, while
the remaining 35% of costs are attributable to disability
and sporadic absenteeism.
CONCLUSIONS: Respiratory infections impose a signif-
icant financial burden on the employer. Resource utiliza-
tion by respiratory infection patients is substantial, not
only for the direct treatment of respiratory infections, but
also for the treatment of co-morbid medical conditions of
these patients. These costs also vary considerably by type
of respiratory infection. The study also shows that respi-
ratory infections impose substantial indirect costs on em-
ployers from work loss associated with these infections.
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